all things to do with diabetes obesity and metabolism
27th September 2020, Dr Chee L Khoo
We know that hyperglycaemia is associated with increased cardiovascular mortality. We also know that in patients with diabetes, hypoglycaemia is also associated with increased cardiovascular morbidity and mortality. What about patients who don’t have diabetes and have low blood glucose (<4.0 mmol/L)? I am sure we all have patients who do not have diabetes but on screening blood tests, have BSL lower than 4.0 mmol/L.…
14th September 2020, Dr Chee L Khoo
We have many patients who have borderline high fasting glucose in their routine check-up. In non-pregnant adults, we have been able to use HbA1c as a generic screening test for type 2 diabetes (T2D) for some time. Unfortunately, neither non-diabetic fasting glucose readings nor HbA1c totally exclude the presence of diabetes. I am sure you have come across patients with non-diabetic fasting glucose and HbA1c but yet fail their oral glucose tolerance test (OGTT).…
14th September 2020, Dr Chee L Khoo
Over the last decade, there has been a push for a less glucocentric management of diabetes. For some, less glucocentric means accepting poorer glycaemic control in our patients with diabetes. It was meant to direct us to not be fixated on managing glucose control without looking at other aspects of the diabetes complications.…
14th September 2020, Dr Chee L Khoo
Tell me this is not, broadly, what you have in mind when you think about gestational diabetes mellitus (GDM). We know that hyperglycaemia and pregnancy does not mix well. GDM is not quite full-blown diabetes in pregnancy but is nonetheless, associated with risks for the mother and infant and with long-term metabolic consequences in both mother and child.…
27th August 2020, Dr Chee L Khoo
I first met him in December 2014 just before he started work at Western Sydney University in 2015. For someone who has just arrived in south west Sydney, I was most impressed to see how well he grasped the problems we have with the quality of care in patients with diabetes in our area.…
26th July 2020, Dr Chee L Khoo
Whenever we think about management of hyperglycaemia in patients with type 2 diabetes (T2D), we usually think about the most efficacious hypoglycaemic agent we can find (and on the PBS). If you look carefully at most management guidelines, lifestyle measures appears at the very top of the algorithm, side by side metformin. Sadly, it is often not the most prominent and usually, dismissed as an important part of the treatment algorithm.…
14th July 2020, Dr Chee L Khoo
A little more than 12 months ago, we discussed how to implement a successful weight loss program in patients with type 2 diabetes following the lines of the successful DiRECT trials from the UK. I presented data to demonstrate that it can all be done in Australian primary care. My study was accepted as an oral presentation at last year’s Australian Diabetes Congress.…
12th July 2020, Dr Chee L Khoo
One month ago, we discussed Ozempic®(semaglutide) as the new GLP-1 agonist kid on the block in the treatment of hyperglycaemia in patients with type 2 diabetes (T2D). We foreshadowed that it will be coming real soon. Well, sooner than I thought. Ozempic® went on the PBS on the 1st July. What we didn’t know was what the restrictions will be when prescribing for patients with T2D.…
29th June 2020, Dr Chee L Khoo
One in three patients with diabetes will develop diabetic foot ulcers (DFU). This typically occurs in the setting of peripheral artery disease, peripheral neuropathy and trauma. Foot ulcers invariably leads to lower extremity amputation (LEA) and both are associated with significant morbidity and mortality. We know that poor glycaemic control contributes to the development of DFU and LEA.…
28th June 2020, Dr Chee L Khoo
In type 1 diabetes (T1D), the β-cell die rapidly from a massive immunological assault and practically all the β-cells are quickly lost and hence, there is an absolute deficiency of insulin secretion. Using auto-antibody screening, we can define T1D. Do you realise that we don’t actually have a definition for type 2 diabetes (T2D).…
12th June 2020, Dr Chee L Khoo
Whenever there are multiple brands of the same class of drugs on the market, one always wonder whether the new kid on the block is a “johnny-come-lately” trying to break into an already crowded market with yet another drug or it’s really a new kid with much better credentials. We already have 4 GLP-1 agonists in Australia and now a fifth one will be out real soon.…
24th May 2020, Dr Chee L Khoo
In primary care, we are frequently preventing disease or at least we try to. Apart from lifestyle measures, we prescribe statins, anti-hypertensive, aspirin and beta-blockers to reduce cardiovascular events. What about arthritis? In patients who do not have arthritis (yet) but are at high risk of degenerative osteoarthritis, is there something we can do to reduce the patients’ risk of progressing to full blown arthritis?…